Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, and the fireside chat will be available on demand beginning June 15 at 7:00 a.m. EDT.
The participation of Helus Pharma's Chief Medical Officer at this prominent neuroscience conference underscores the company's commitment to advancing its pipeline of proprietary NSAs. These synthetic molecules are designed to activate serotonin pathways believed to promote neuroplasticity, offering potential new treatments for depression, anxiety, and other mental health conditions. Helus Pharma aims to address the large unmet need in mental health care through its innovative approach.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, the company is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's website at www.helus.com or follow the team on social media platforms. The full press release is available at https://ibn.fm/KsnJW.
This news is important as it highlights Helus Pharma's ongoing engagement with the investment and medical communities, showcasing its leadership in developing potential breakthrough treatments for mental health disorders. The company's participation in the H.C. Wainwright Neuro Perspectives Conference provides a platform to discuss its clinical programs and the potential impact of its novel serotonergic agonists on patient outcomes.
